| 71.06 1.13 (1.62%) | 01-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 91.19 | 1-year : | 99.75 |
| Resists | First : | 78.07 | Second : | 85.41 |
| Pivot price | 72.53  |
|||
| Supports | First : | 66.2 | Second : | 55.08 |
| MAs | MA(5) : | 70.52 |
MA(20) : | 73.91 |
| MA(100) : | 64.58 |
MA(250) : | 48.11 |
|
| MACD | MACD : | -1.6 |
Signal : | -1 |
| %K %D | K(14,3) : | 41.7 |
D(3) : | 37.4 |
| RSI | RSI(14): 44.8 |
|||
| 52-week | High : | 103 | Low : | 19.44 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ KYMR ] has closed above bottom band by 34.2%. Bollinger Bands are 32.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 71.3 - 71.64 | 71.64 - 71.96 |
| Low: | 67.43 - 67.82 | 67.82 - 68.18 |
| Close: | 70.42 - 71.03 | 71.03 - 71.61 |
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Thu, 22 Jan 2026
Assessing Kymera Therapeutics (KYMR) Valuation After Milestone Updates For KT-621 And Partnered IRAK4 Programs - Sahm
Tue, 20 Jan 2026
Kymera Therapeutics director Esposito sells $373k in shares - Investing.com
Thu, 15 Jan 2026
Kymera Therapeutics, Inc. (KYMR) up 28% in 3M, analysts see further upside - MSN
Thu, 15 Jan 2026
BTIG Reiterates Buy Rating for Kymera Therapeutics (KYMR) with $ - GuruFocus
Thu, 15 Jan 2026
Is Kymera Therapeutics (KYMR) Turning Its Immunology Pipeline Into a Durable Platform Advantage? - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 80 (M) |
| Held by Insiders | 4.845e+007 (%) |
| Held by Institutions | 2.2 (%) |
| Shares Short | 8,690 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.2154e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 207.8 % |
| Return on Equity (ttm) | -19.3 % |
| Qtrly Rev. Growth | 4.373e+007 % |
| Gross Profit (p.s.) | -11.76 |
| Sales Per Share | -14.46 |
| EBITDA (p.s.) | -1.17486e+008 |
| Qtrly Earnings Growth | -3.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -228 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -4.92 |
| Price to Cash Flow | 11.96 |
| Dividend | 0 |
| Forward Dividend | 7.94e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|